|
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma Clinical Trials Facts presented on Clinical Trials Search isn't designed to be a substitute for proven healthcare advice, calls or treatment using a real mD. We aren't mDs. Always confer with your physician on Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma conditions. Clinical Trials Search.org is a website dedicated to listing clinical research studies in human subjects. Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma Clinical research trials and Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma healthcare trials happen in a lot of of localities across the United States of America. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / undertakings is to answer particular human medical questions. Clinical trials are a popular manner for doctors, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, such as Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma. Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma Clinical Trials and other clinical trials allow volunteers to get healthcare treatment alternatives before they are available to the general public. Most times the participants receive treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma clinical trial. Human subjects often receive the most effective healthcare possible for their Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma condition. Risks are a reality, nonetheless, and may include more or frequent dr. calls, healthcare hazards (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with rigorous guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "T" Clinical Trials Conditions > Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma  Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
For Condition: adult anaplastic oligodendroglioma,adult glioblastoma multiforme,Mixed Gliomas,adult anaplastic astrocytoma,recurrent adult brain tumor
Status: Recruiting
Sponsor(s): North American Brain Tumor Consortium , National Cancer Institute (NCI)
Synopsis: RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells. PURPOSE: Phase I/II trial to study the effectiveness of temozolomide plus irinotecan in treating patients who have recurrentmalignantglioma.
Details: OBJECTIVES: - Determine the maximum tolerated dose and dose-limiting toxicity of irinotecan when administered with temozolomide in patients with recurrent malignant glioma. - Determine the safety profile of this regimen in this patient population. - Determine the efficacy of this treatment regimen as measured by 6-month progression-free survival and objective tumor response in these patients. - Characterize the pharmacokinetics of this treatment regimen in these patients. - Determine the antitumor activity of this treatment regimen in these patients. OUTLINE: This is a multicenter, dose-escalation study of irinotecan. Patients are stratified according to concurrent enzyme-inducing anti-epileptic drugs (EIAEDs) (e.g., phenytoin, phenobarbital, carbamazepine, or primidone) (yes vs no). In phase I of the study, patients receive oral temozolomide on days 1-5 and irinotecan IV over 90 minutes on days 1 and 14. Treatment continues every 28 days for up to 1 year in the absence of disease progression or unacceptable toxicity. Patients concurrently on EIAEDs undergo dose escalation of irinotecan. Cohorts of 3 to 6 patients receive escalating doses of irinotecan until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 6 patients experience dose-limiting toxicity. In phase II of the study, patients receive the same treatment as in phase I at the MTD. Patients are followed every 2 months for 1 year, every 3 months for 1 year, every 4 months for 1 year, every 6 months until progression, and then every 4 months for survival. PROJECTED ACCRUAL: A total of 30 patients will be accrued for phase I within 10 months and 48 patients will be accrued for phase II within 6-8 months.
Eligibility:
Study Type: Interventional, Treatment
Minimum Age/Maximum Age: 18 Years/
Genders: Both
Protocol Entry Criteria: DISEASE CHARACTERISTICS: - Histologically confirmed supratentorial malignant primary glioma of one of the following subtypes: - Glioblastoma multiforme - Anaplastic astrocytoma - Anaplastic oligodendroglioma - Mixed malignant glioma - Original histology of low-grade glioma allowed if subsequent histological confirmation of malignant glioma - Measurable recurrent or residual primary disease by MRI - Lesions with clearly defined margins - Evidence of tumor recurrence or progression by MRI or CT scan - Confirmation of true progressive disease by PET or thallium scan, magnetic resonance spectroscopy, or surgical documentation after prior interstitial brachytherapy or stereotactic radiosurgery - No more than 3 relapses after prior chemotherapy/cytotoxic therapy (including polifeprosan 20 with carmustine implant) for phase I and no more than 2 relapses for phase II PATIENT CHARACTERISTICS: Age: - 18 and over Performance status: - Karnofsky 60-100% Life expectancy: - Not specified Hematopoietic: - WBC at least 3,000/mm^3 - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 - Hemoglobin at least 10 g/dL Hepatic: - Bilirubin no greater than 1.5 mg/dL - SGOT no greater than 2 times upper limit of normal Renal: - Creatinine no greater than 1.5 mg/dL Cardiovascular: - No uncontrolled hypertension, unstable angina, or symptomatic congestive heart failure - No myocardial infarction within the past 6 months - No serious uncontrolled cardiac arrhythmia Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use effective contraception - No mental incapacitation - HIV negative - No AIDS-related disease - No significant ongoing alcoholism or substance abuse - No severe nonmalignant systemic disease - No active infection - No other severe disease that would preclude study PRIOR CONCURRENT THERAPY: Biologic therapy: - At least 1 week since prior interferon or thalidomide and recovered - No concurrent anticancer immunotherapy - No concurrent sargramostim (GM-CSF) - No concurrent prophylactic filgrastim (G-CSF) during first course of study therapy Chemotherapy: - See Disease Characteristics - Recovered from prior chemotherapy - At least 2 weeks since prior vincristine - At least 3 weeks since prior procarbazine - At least 4 weeks since prior cytotoxic chemotherapy (6 weeks for nitrosourea) - Prior radiosensitizers allowed - No prior temozolomide or irinotecan - No other concurrent anticancer chemotherapy Endocrine therapy: - At least 1 week since prior tamoxifen and recovered - No concurrent anticancer hormonal therapy - Phase II: - Non-increasing dose of corticosteroids allowed Radiotherapy: - See Disease Characteristics - At least 4 weeks since prior radiotherapy and recovered - No concurrent anticancer radiotherapy Surgery: - See Disease Characteristics - At least 1-3 weeks since prior surgical resection and recovered Other: - At least 1 week since prior noncytotoxic agents (e.g., isotretinoin) and recovered - Concurrent enzyme-inducing anti-epileptic drugs with or without steroids allowed - No concurrent valproic acid as a single agent - No concurrent medication that would preclude study (e.g., nonsteroidal immunosuppressive agents) - No other concurrent investigational drugs - No concurrent participation in other clinical study
Total Enrollment:
Location and Contact Information:
Overall Study Official:
Wai-KwanYung, Study Chair, M.D. Anderson Cancer Center
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support*Recruiting*
Bethesda, Maryland, 20892-1182
United States
RecruitingPatient Recruitment 1-888-NCI-1937
Jonsson Comprehensive Cancer Center, UCLA*Recruiting*
Los Angeles, California, 90095
United States
RecruitingTimothy Cloughesy 310-825-5321
UCSF Comprehensive Cancer Center*Recruiting*
San Francisco, California, 94115
United States
RecruitingMichael Prados 415-353-9510
Memorial Sloan-Kettering Cancer Center*Recruiting*
New York City, New York, 10021
United States
RecruitingLisa DeAngelis 212-639-7123
University of Texas - MD Anderson Cancer Center*Recruiting*
Houston, Texas, 77030-4009
United States
RecruitingWai-Kwan Yung 713-794-1285
Dana-Farber/Harvard Cancer Center at Dana Farber Cancer Institute*Recruiting*
Boston, Massachusetts, 02115
United States
RecruitingPatrick Wen 617-632-2166
Hillman Cancer Center at University of Pittsburgh Cancer Institute*Recruiting*
Pittsburgh, Pennsylvania, 15232
United States
RecruitingFrank Lieberman 412-692-2600
University of Texas Health Science Center at San Antonio*Recruiting*
San Antonio, Texas, 78284-6220
United States
RecruitingJohn Kuhn 210-567-8355
University of Wisconsin Comprehensive Cancer Center*Recruiting*
Madison, Wisconsin, 53792
United States
RecruitingMinesh Mehta 608-263-8500
Additional Information:
Study ID Numbers: CDR0000068037; NABTC-9907,UCLA-0006095
Study Start Date:
Record last reviewed: September 2001
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00006025
Other Adult Anaplastic AstrocytomaStudies:
1. Surgery, Radiation Therapy, and Chemotherapy With or Without Photodynamic Therapy in Treating Patients With Newly Diagnosed or Recurrent Malignant Supratentorial Gliomas
2. Carmustine Plus O6-benzylguanine in Treating Patients With Recurrent or Progressive Glioma
3. Antineoplaston Therapy in Treating Patients With Anaplastic Astrocytoma
4. Irinotecan Plus Temozolomide in Treating Patients With Recurrent Primary Malignant Glioma
5. Temozolomide in Treating Patients With Recurrent Malignant Glioma
Related Studies:
Other adult anaplastic astrocytoma Clinical Trials
Other California Clinical Trials
Other San Francisco Clinical Trials
Temozolomide Plus Irinotecan in Treating Patients With Recurrent Malignant Glioma
|
|
|
|
|
|
|
|
